anti-CD19 CAR-NK
Phase 1Cell therapy
anti-CD19 CAR-NK is one of 60 biologic programs targeting Autoimmune Disease. It is currently in Phase 1.
2
Indications
5
Total Trials
3
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
70 competitors in Autoimmune Disease
#DrugCompanyPhaseTrials
1Atgam
NovartisPhase 2
Cytosar
TevaPhase 2
Rayos
RRoxane Laboratories
Phase 2
Vepesid
AAvyxa
Phase 2
Alkeran
AApotex Inc.
Phase 2
Bicnu
MMelissa K Accordino
Phase 2
Fludara
SanofiPhase 1
CAR-T Cell
PPersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 1
CD19 CAR-T Cells
CChongqing Precision Biotech Co., Ltd
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Refractory3 trials
Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT04887012·25 enrolled
Autoimmune Disease1 trial
Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06614270·15 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti-CD19 CAR-NK. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details